Esophageal Adenocarcinoma — Trials

Esophageal Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 70
Recruiting: 45
Ph III recruiting: 4
Growth YoY: —
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (27)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07594548	Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	not yet recruiting	Phase 1	18	Northwestern UniversityOTHER	1	May 18, 2026	clinicaltrials

Data updated 23 days agoSource updated May 18, 2026source: clinicaltrials